Bolt Biotherapeutics (BOLT) Net Income (2020 - 2026)
Bolt Biotherapeutics (BOLT) posted Net Income of -$8.6 million for Q1 2026, down 0.93% sequentially from -$8.6 million in Q4 2025, and up 29.71% YoY from -$6.7 million in Q1 2025.
Bolt Biotherapeutics (BOLT) Net Income (2020 - 2026) Analysis & Trends
Bolt Biotherapeutics has reported Net Income for 7 years, with the latest figure at -$8.6 million in Q1 2026.
- Quarterly Net Income rose 29.71% year-over-year to -$8.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$100.0 million (down 41.02% YoY) and the FY2025 annual result came in at -$137.2 million, up 19.22% from the prior year.
- Net Income fell to -$8.6 million in Q1 2026 per BOLT's latest filing, from -$8.6 million in the prior quarter.
- Over five years, Net Income peaked at -$8.6 million in Q4 2025 and troughed at -$58.2 million in Q2 2022.
- A 5-year average of -$30.3 million and a median of -$21.5 million in 2022 frame the typical range for Net Income.
- The sharpest annual moves came in 2024 and 2025: Net Income surged 66.69% in 2024, then plunged 140.89% in 2025.
- Over 5 years, Net Income stood at -$21.5 million in 2022, then soared by 44.92% to -$11.8 million in 2023, then slumped by 73.61% to -$20.6 million in 2024, then jumped by 58.32% to -$8.6 million in 2025, then fell by 0.93% to -$8.6 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$8.6 million, -$8.6 million, and -$40.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -355.03 Mn |
| 10 | Bolt Biotherapeutics | 5.48 Mn | 5.48 Mn | - | -8.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -37.06 Mn |
| Mar 31, 2026 | -8.65 Mn |
| Dec 31, 2025 | -8.57 Mn |
| Sep 30, 2025 | -40.07 Mn |
| Jun 30, 2025 | -42.76 Mn |
| Mar 31, 2025 | -12.30 Mn |
| Dec 31, 2024 | -20.56 Mn |
| Sep 30, 2024 | -16.63 Mn |
| Jun 30, 2024 | -21.45 Mn |
| Mar 31, 2024 | -16.69 Mn |
| Dec 31, 2023 | -11.84 Mn |
| Sep 30, 2023 | -48.88 Mn |
| Jun 30, 2023 | -51.77 Mn |
| Mar 31, 2023 | -50.09 Mn |
| Dec 31, 2022 | -21.50 Mn |
| Sep 30, 2022 | -57.78 Mn |
| Jun 30, 2022 | -58.24 Mn |
| Mar 31, 2022 | -27.91 Mn |
| Dec 31, 2021 | -28.99 Mn |
| Sep 30, 2021 | -62.94 Mn |